The MiningNewsWire Podcast

NetworkNewsWire Editorial Coverage: Already proven to be a revolutionary treatment for type 2 diabetes and weight loss, glucagon-like peptide-1 (GLP-1) agonists now appear to have a multitude of potential blockbuster therapeutic uses, according to recent research. Obviously, diabetes remains a primary indication, given the massive global need. However, the impact of this extraordinary molecule extends far beyond type 2 diabetes. The reach of GLP-1 drugs has widened in ways its inventors likely never imagined. Clinical trials are underway testing GLP-1 drugs to treat Alzheimer’s, Parkinson’s, and even drug addiction, plus there are strong indications of therapeutic efficacy in heart disease and chronic kidney disease, as well as a wide range of other conditions, including weight loss. The newfound applications of this super-drug re-enforce both the reach and impact of Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile). By supercharging GLP-1 drugs with its DehydraTECH(TM) drug-delivery formulation and processing technology, Lexaria intends to improve both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. With several key studies on the near-term horizon, Lexaria has positioned itself in the midst of these market opportunities alongside others changing the landscape, such as Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), AstraZeneca PLC (NASDAQ: AZN) and Novo Nordisk (NYSE: NVO).

• GLP-1 agonists are the hottest drugs in healthcare today, with uses targeting multibillion-dollar diabetes and obesity markets and much more.

Click here to view the custom infographic of the Lexaria Bioscience Corp. editorial.

NetworkNewsWire Editorial Coverage: Already proven to be a revolutionary treatment for type 2 diabetes and weight loss, glucagon-like peptide-1 (GLP-1) agonists now appear to have a multitude of potential blockbuster therapeutic uses, according to recent research. Obviously, diabetes remains a primary indication, given the massive global need. However, the impact of this extraordinary molecule extends far beyond type 2 diabetes. The reach of GLP-1 drugs has widened in ways its inventors likely never imagined. Clinical trials are underway testing GLP-1 drugs to treat Alzheimer’s, Parkinson’s, and even drug addiction, plus there are strong indications of therapeutic efficacy in heart disease and chronic kidney disease, as well as a wide range of other conditions, including weight loss. The newfound applications of this super-drug re-enforce both the reach and impact of Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile). By supercharging GLP-1 drugs with its DehydraTECH(TM) drug-delivery formulation and processing technology, Lexaria intends to improve both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. With several key studies on the near-term horizon, Lexaria has positioned itself in the midst of these market opportunities alongside others changing the landscape, such as Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), AstraZeneca PLC (NASDAQ: AZN) and Novo Nordisk (NYSE: NVO).

• GLP-1 agonists are the hottest drugs in healthcare today, with uses targeting multibillion-dollar diabetes and obesity markets and much more.

Click here to view the custom infographic of the Lexaria Bioscience Corp. editorial.

CNS Pharmaceuticals (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, recently announced the recommendation of the independent Data Safety Monitoring Board (DSMB) that the Company’s ongoing global, potentially pivotal trial of the investigational agent, Berubicin for the treatment of glioblastoma multiforme (GBM) continue without any modification.

The recommendation follows the DSMB’s pre-specified futility analysis of unblinded (to the DSMB only) efficacy and safety data in the Company’s trial of Berubicin versus Lomustine, a standard of care in patients with recurrent GBM. More specifically, the DSMB reviewed the primary endpoint of overall survival (OS) and secondary efficacy measures progression-free survival (PFF) and overall response rate (ORR), as well as safety data in evaluable patients. In order to support continuing the trial, Berubicin’s efficacy had to be at least comparable to Lomustine’s on the primary endpoint (OS).

To read the original press release, visit: https://www.nnw.fm/Sj7iP

Please see full terms of use and disclaimers on the IBN website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer

CNS Pharmaceuticals (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, recently announced the recommendation of the independent Data Safety Monitoring Board (DSMB) that the Company’s ongoing global, potentially pivotal trial of the investigational agent, Berubicin for the treatment of glioblastoma multiforme (GBM) continue without any modification.

The recommendation follows the DSMB’s pre-specified futility analysis of unblinded (to the DSMB only) efficacy and safety data in the Company’s trial of Berubicin versus Lomustine, a standard of care in patients with recurrent GBM. More specifically, the DSMB reviewed the primary endpoint of overall survival (OS) and secondary efficacy measures progression-free survival (PFF) and overall response rate (ORR), as well as safety data in evaluable patients. In order to support continuing the trial, Berubicin’s efficacy had to be at least comparable to Lomustine’s on the primary endpoint (OS).

To read the original press release, visit: https://www.nnw.fm/Sj7iP

Please see full terms of use and disclaimers on the IBN website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer

NetworkNewsWire Editorial Coverage: The prestigious New England Journal of Medicine recently published results of a large study of 2,539 adults wherein weight loss of 49 to 52 pounds was a common outcome. With more than 37 million Americans suffering from diabetes, and with obesity at epidemic levels, it’s little wonder that millions of people are singing their praises of the new class of drugs responsible for these outrageously positive outcomes. GLP-1 agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with type 2 diabetes but are also helping treat obesity. Seems everyone is excited about controlling blood sugar and easily losing weight. But there may be an even better avenue to increased effectiveness and better outcomes. Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), a global innovator in drug-delivery platforms, began diabetes-related formal studies last year with its DehydraTECH(TM) platform, which showed reduced blood-sugar levels and lowered body weight. With such encouraging early results, Lexaria is planning to launch new human and animal studies to examine whether DehydraTECH processing can make GLP-1 drugs such as semaglutide even better. Lexaria’s heavily-patented DehydraTECH drug delivery technology might  improve bioavailability, lower costs, and enhance tolerability, weight-loss potential and management of diabetes and other health conditions. DehydraTECH may become a game changer in the multibillion-dollar GLP-1 drug market and could potentially lead to a collaboration with a dominant player in the space, such as Novo Nordisk (NYSE: NVO, Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), or AstraZeneca PLC (NASDAQ: AZN).

• Lexaria’s DehydraTECH is easily integrated into oral product manufacturing processes to better deliver API payloads to improve bioavailability, reduce side effects and more.

NetworkNewsWire Editorial Coverage: The prestigious New England Journal of Medicine recently published results of a large study of 2,539 adults wherein weight loss of 49 to 52 pounds was a common outcome. With more than 37 million Americans suffering from diabetes, and with obesity at epidemic levels, it’s little wonder that millions of people are singing their praises of the new class of drugs responsible for these outrageously positive outcomes. GLP-1 agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with type 2 diabetes but are also helping treat obesity. Seems everyone is excited about controlling blood sugar and easily losing weight. But there may be an even better avenue to increased effectiveness and better outcomes. Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), a global innovator in drug-delivery platforms, began diabetes-related formal studies last year with its DehydraTECH(TM) platform, which showed reduced blood-sugar levels and lowered body weight. With such encouraging early results, Lexaria is planning to launch new human and animal studies to examine whether DehydraTECH processing can make GLP-1 drugs such as semaglutide even better. Lexaria’s heavily-patented DehydraTECH drug delivery technology might  improve bioavailability, lower costs, and enhance tolerability, weight-loss potential and management of diabetes and other health conditions. DehydraTECH may become a game changer in the multibillion-dollar GLP-1 drug market and could potentially lead to a collaboration with a dominant player in the space, such as Novo Nordisk (NYSE: NVO, Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), or AstraZeneca PLC (NASDAQ: AZN).

• Lexaria’s DehydraTECH is easily integrated into oral product manufacturing processes to better deliver API payloads to improve bioavailability, reduce side effects and more.

Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions, today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio news release covers Longeveron’s recent announcement of positive top-line results from its Phase 2a trial of its investigational product Lomecel-B™ for the treatment of mild Alzheimer’s disease.

“We believe these results provide important validation of both the safety and therapeutic potential of Lomecel-B™ in the treatment of Alzheimer’s disease and provide a robust foundation for additional clinical trials in this and other indications,” Wa’el Hashad, CEO of Longeveron, stated in the news release. “We look forward to announcing additional biomarker data from this trial, anticipated to be later this month, which may further characterize the clinical effects of Lomecel-B™ in this study population. With our Phase 2 ELPIS II trial in HLHS moving toward anticipated completion in 2024, and our Phase 2 program in Aging-related Frailty progressing in Japan as well, we look forward to meaningful milestones in the near term and to fully realizing the therapeutic potential of Lomecel-B™.”

To read the original press release, visit: https://nnw.fm/ckhHp

Please see full terms of use and disclaimers on the IBN website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer

Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions, today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio news release covers Longeveron’s recent announcement of positive top-line results from its Phase 2a trial of its investigational product Lomecel-B™ for the treatment of mild Alzheimer’s disease.

“We believe these results provide important validation of both the safety and therapeutic potential of Lomecel-B™ in the treatment of Alzheimer’s disease and provide a robust foundation for additional clinical trials in this and other indications,” Wa’el Hashad, CEO of Longeveron, stated in the news release. “We look forward to announcing additional biomarker data from this trial, anticipated to be later this month, which may further characterize the clinical effects of Lomecel-B™ in this study population. With our Phase 2 ELPIS II trial in HLHS moving toward anticipated completion in 2024, and our Phase 2 program in Aging-related Frailty progressing in Japan as well, we look forward to meaningful milestones in the near term and to fully realizing the therapeutic potential of Lomecel-B™.”

To read the original press release, visit: https://nnw.fm/ckhHp

Please see full terms of use and disclaimers on the IBN website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer

In volatile economic conditions, smart money seeks stability and moves to safe havens. Historically, one of the safest places and most stable spaces during economic uncertainty is gold, a highly liquid asset that preserves and even increases in value over time and carries no credit risk. The precious metal benefits from multiple levers of demand such as gold jewelry, tech/industrial use and a reserve asset as well as a strategic investment. History has shown that gold’s variable demand pressures enhance a portfolio by improving diversification, providing liquidity and delivering long-term returns. Reacting to uncertainties, many gold mining companies, including GEMXX Corp. (OTC: GEMZ) (profile), have enjoyed significant growth during the recent volatility. Exploding past startup phase and achieving global growth in mere months, GEMXX is fast approaching a holy grail that differentiates GEMXX from all others in the gold space – a vertically integrated mining company – a unique mine-to-market enterprise that specializes in gold and gemstone mining as well as jewelry creation, production and global sales. GEMXX owns and controls every aspect of the process from gold mining and gemstone finishing to jewelry manufacturing and global distribution. Other larger mining companies may not have the unique vertical integration of GEMXX but are still seeing success in the precious metal sector including Agnico Eagle Mines Ltd. (NYSE: AEM), which recently reported record second-quarter numbers; Barrick Gold (NYSE: GOLD), which anticipates a second half of the year performance that surpasses its first; Newmont Mining (NYSE: NEM), which has received required approvals on a key acquisition announced earlier this year; and Franco-Nevada Corp. (NYSE: FNV), which has established a business model that provides investors with gold price and exploration optionality while limiting exposure to cost inflation.

To view the full editorial, visit https://ibn.fm/trQPF

In volatile economic conditions, smart money seeks stability and moves to safe havens. Historically, one of the safest places and most stable spaces during economic uncertainty is gold, a highly liquid asset that preserves and even increases in value over time and carries no credit risk. The precious metal benefits from multiple levers of demand such as gold jewelry, tech/industrial use and a reserve asset as well as a strategic investment. History has shown that gold’s variable demand pressures enhance a portfolio by improving diversification, providing liquidity and delivering long-term returns. Reacting to uncertainties, many gold mining companies, including GEMXX Corp. (OTC: GEMZ) (profile), have enjoyed significant growth during the recent volatility. Exploding past startup phase and achieving global growth in mere months, GEMXX is fast approaching a holy grail that differentiates GEMXX from all others in the gold space – a vertically integrated mining company – a unique mine-to-market enterprise that specializes in gold and gemstone mining as well as jewelry creation, production and global sales. GEMXX owns and controls every aspect of the process from gold mining and gemstone finishing to jewelry manufacturing and global distribution. Other larger mining companies may not have the unique vertical integration of GEMXX but are still seeing success in the precious metal sector including Agnico Eagle Mines Ltd. (NYSE: AEM), which recently reported record second-quarter numbers; Barrick Gold (NYSE: GOLD), which anticipates a second half of the year performance that surpasses its first; Newmont Mining (NYSE: NEM), which has received required approvals on a key acquisition announced earlier this year; and Franco-Nevada Corp. (NYSE: FNV), which has established a business model that provides investors with gold price and exploration optionality while limiting exposure to cost inflation.

To view the full editorial, visit https://ibn.fm/trQPF